News articles about Mylan (NASDAQ:MYL) have trended somewhat positive on Sunday, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Mylan earned a news sentiment score of 0.18 on Accern’s scale. Accern also gave media coverage about the company an impact score of 45.8307916785426 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
These are some of the news headlines that may have effected Accern Sentiment’s scoring:
- Teva’s Stock Jumps Following Report on Planned Cuts – CTech (calcalistech.com)
- Retropharyngeal Abscess Market which is expected to reach USD 5.9 Billion during 2017 to 2023 (medgadget.com)
- UnitedHealth buys DaVita for $4.9B (finance.yahoo.com)
- Financial Survey: Mylan (MYL) vs. NephroGenex (NRXGQ) (americanbankingnews.com)
- Head to Head Analysis: NephroGenex (NRXGQ) vs. Mylan (MYL) (americanbankingnews.com)
Several equities research analysts recently commented on MYL shares. Zacks Investment Research lowered shares of Mylan from a “buy” rating to a “hold” rating in a research report on Wednesday, November 8th. Cantor Fitzgerald set a $34.00 target price on shares of Mylan and gave the company a “hold” rating in a report on Tuesday, October 31st. Citigroup upgraded shares of Mylan from a “neutral” rating to a “buy” rating and upped their target price for the company from $36.00 to $42.00 in a report on Wednesday, August 16th. Mizuho restated a “buy” rating and issued a $37.00 target price on shares of Mylan in a report on Tuesday, October 24th. Finally, Royal Bank Of Canada upped their target price on shares of Mylan from $32.00 to $37.00 and gave the company a “sector perform” rating in a report on Tuesday, November 7th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and thirteen have assigned a buy rating to the company. Mylan has an average rating of “Buy” and an average price target of $41.49.
Mylan (NASDAQ:MYL) traded up $1.30 during trading on Friday, hitting $38.67. The stock had a trading volume of 6,963,386 shares, compared to its average volume of 4,923,973. The company has a debt-to-equity ratio of 1.05, a quick ratio of 0.95 and a current ratio of 1.46. The stock has a market cap of $20,743.98, a PE ratio of 8.23, a P/E/G ratio of 2.12 and a beta of 1.38. Mylan has a 12 month low of $29.39 and a 12 month high of $45.87.
Mylan (NASDAQ:MYL) last issued its quarterly earnings results on Monday, November 6th. The company reported $1.10 EPS for the quarter, missing analysts’ consensus estimates of $1.20 by ($0.10). The business had revenue of $2.99 billion for the quarter, compared to analyst estimates of $3.09 billion. Mylan had a net margin of 7.28% and a return on equity of 20.63%. Mylan’s revenue for the quarter was down 2.3% on a year-over-year basis. During the same period last year, the business posted $1.38 earnings per share. equities analysts forecast that Mylan will post 4.56 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: “Mylan (MYL) Earning Somewhat Positive Media Coverage, Accern Reports” was reported by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this report on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this report can be read at https://transcriptdaily.com/2017/12/11/mylan-myl-earning-somewhat-positive-media-coverage-accern-reports.html.
Mylan Company Profile
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Receive News & Ratings for Mylan N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan N.V. and related companies with MarketBeat.com's FREE daily email newsletter.